2025 annual financial data
Inhibrx Biosciences 2025 Net margin
Direct answer
Net margin was -10,773.46%.
Operating income was -135,025,000 USD and net income was -140,055,000 USD.
Operating cash flow was -129,794,000 USD.
Get free Inhibrx Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,300,000 USD
- Operating income
- -135,025,000 USD
- Net income
- -140,055,000 USD
- Operating cash flow
- -129,794,000 USD